A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 30 May 2014 Biomarkers information updated
- 25 Oct 2013 Planned end date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.